Market Overview

UPDATE: Goldman Sachs Upgrades SUPERVALU to Neutral Following Share Selloff

Related SVU
Benzinga's Weekend M&A Chatter
Jim Cramer Shares His Thoughts On Horizon Pharma And SUPERVALU

Goldman Sachs upgraded its rating on SUPERVALU (NYSE: SVU) from Sell to Neutral but lowered its price target from $5 to $3.

Goldman Sachs noted, "We are upgrading SVU to Neutral from Sell as the recent sell-off leaves the risk-reward ratio more balanced. We continue to see a combination of secular and cyclical headwinds converging with SVU's higher financial leverage to pressure results and limit free cash flow available to shareholders. However, the market appears to be discounting this scenario with the shares now trading at an 8% discount to the peer group at 5.7X CY13 pension-adj. EV/EBITDA and a 13% discount on a straight EV/EBITDA valuation of 4.1X. Since adding SVU to the Sell List on April 29, 2012, the stock is -62% vs. the S&P -3%; and -75% vs. S&P +3% over the past year."

SUPERVALU closed at $2.32 on Friday.

Latest Ratings for SVU

Jul 2015Morgan StanleyUpgradesUnderweightEqual-weight
Jul 2015Pivotal ResearchInitiates Coverage onBuy
Jun 2015Guggenheim SecuritiesInitiates Coverage onNeutral

View More Analyst Ratings for SVU
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Upgrades Intraday Update Analyst Ratings


Related Articles (SVU)

View Comments and Join the Discussion!

Get Benzinga's Newsletters